<script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app17.us.archive.org';v.server_ms=311;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include --><!-- BEGIN WAYBACK TOOLBAR INSERT -->
<script type="text/javascript" src="/static/js/timestamp.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/graph-calc.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/auto-complete.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/toolbar.js?v=1531166943.0" charset="utf-8"></script>

<style type="text/css">
body {
  margin-top:0 !important;
  padding-top:0 !important;
  /*min-width:800px !important;*/
}
.wb-autocomplete-suggestions {
    text-align: left; cursor: default; border: 1px solid #ccc; border-top: 0; background: #fff; box-shadow: -1px 1px 3px rgba(0,0,0,.1);
    position: absolute; display: none; z-index: 2147483647; max-height: 254px; overflow: hidden; overflow-y: auto; box-sizing: border-box;
}
.wb-autocomplete-suggestion { position: relative; padding: 0 .6em; line-height: 23px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis; font-size: 1.02em; color: #333; }
.wb-autocomplete-suggestion b { font-weight: bold; }
.wb-autocomplete-suggestion.selected { background: #f0f0f0; }
</style>
<div id="wm-ipp" lang="en" style="display:none;direction:ltr;">
<div style="position:fixed;left:0;top:0;right:0;">
<div id="wm-ipp-inside">
  <div style="position:relative;">
    <div id="wm-logo" style="float:left;width:130px;padding-top:10px;">
      <a href="/web/" title="Wayback Machine home page"><img src="/static/images/toolbar/wayback-toolbar-logo.png" alt="Wayback Machine" width="110" height="39" border="0" /></a>
    </div>
    <div class="r" style="float:right;">
      <div id="wm-btns" style="text-align:right;height:25px;">
                  <div id="wm-save-snapshot-success">success</div>
          <div id="wm-save-snapshot-fail">fail</div>
          <a href="#"
             onclick="__wm.saveSnapshot('https://www.guideline.gov/summaries/downloadcontent/ngc-10342?contentType=xml', '20160930191901')"
             title="Share via My Web Archive"
             id="wm-save-snapshot-open"
          >
            <span class="iconochive-web"></span>
          </a>
          <a href="https://archive.org/account/login.php"
             title="Sign In"
             id="wm-sign-in"
          >
            <span class="iconochive-person"></span>
          </a>
          <span id="wm-save-snapshot-in-progress" class="iconochive-web"></span>
        	<a href="http://faq.web.archive.org/" title="Get some help using the Wayback Machine" style="top:-6px;"><span class="iconochive-question" style="color:rgb(87,186,244);font-size:160%;"></span></a>
	<a id="wm-tb-close" href="#close" onclick="__wm.h(event);return false;" style="top:-2px;" title="Close the toolbar"><span class="iconochive-remove-circle" style="color:#888888;font-size:240%;"></span></a>
      </div>
      <div id="wm-share" style="text-align:right;">
	<a href="#" onclick="window.open('https://www.facebook.com/sharer/sharer.php?u=https://web.archive.org/web/20160930191901/https://www.guideline.gov/summaries/downloadcontent/ngc-10342?contentType=xml', '', 'height=400,width=600'); return false;" title="Share on Facebook" style="margin-right:5px;" target="_blank"><span class="iconochive-facebook" style="color:#3b5998;font-size:160%;"></span></a>
	<a href="#" onclick="window.open('https://twitter.com/intent/tweet?text=https://web.archive.org/web/20160930191901/https://www.guideline.gov/summaries/downloadcontent/ngc-10342?contentType=xml&amp;via=internetarchive', '', 'height=400,width=600'); return false;" title="Share on Twitter" style="margin-right:5px;" target="_blank"><span class="iconochive-twitter" style="color:#1dcaff;font-size:160%;"></span></a>
      </div>
    </div>
    <table class="c" style="">
      <tbody>
	<tr>
	  <td class="u" colspan="2">
	    <form target="_top" method="get" action="/web/submit" name="wmtb" id="wmtb"><input type="text" name="url" id="wmtbURL" value="https://www.guideline.gov/summaries/downloadcontent/ngc-10342?contentType=xml" onfocus="this.focus();this.select();" /><input type="hidden" name="type" value="replay" /><input type="hidden" name="date" value="20160930191901" /><input type="submit" value="Go" /></form>
	  </td>
	  <td class="n" rowspan="2" style="width:110px;">
	    <table>
	      <tbody>
		<!-- NEXT/PREV MONTH NAV AND MONTH INDICATOR -->
		<tr class="m">
		  <td class="b" nowrap="nowrap">Aug</td>
		  <td class="c" id="displayMonthEl" title="You are here: 19:19:01 Sep 30, 2016">SEP</td>
		  <td class="f" nowrap="nowrap">Oct</td>
		</tr>
		<!-- NEXT/PREV CAPTURE NAV AND DAY OF MONTH INDICATOR -->
		<tr class="d">
		  <td class="b" nowrap="nowrap"><img src="/static/images/toolbar/wm_tb_prv_off.png" alt="Previous capture" width="14" height="16" border="0" /></td>
		  <td class="c" id="displayDayEl" style="width:34px;font-size:24px;white-space:nowrap;" title="You are here: 19:19:01 Sep 30, 2016">30</td>
		  <td class="f" nowrap="nowrap"><img src="/static/images/toolbar/wm_tb_nxt_off.png" alt="Next capture" width="14" height="16" border="0" /></td>
		</tr>
		<!-- NEXT/PREV YEAR NAV AND YEAR INDICATOR -->
		<tr class="y">
		  <td class="b" nowrap="nowrap">2015</td>
		  <td class="c" id="displayYearEl" title="You are here: 19:19:01 Sep 30, 2016">2016</td>
		  <td class="f" nowrap="nowrap">2017</td>
		</tr>
	      </tbody>
	    </table>
	  </td>
	</tr>
	<tr>
	  <td class="s">
	    	    <div id="wm-nav-captures">
	      	      <a class="t" href="/web/20160930191901*/https://www.guideline.gov/summaries/downloadcontent/ngc-10342?contentType=xml" title="See a list of every capture for this URL">1 capture</a>
	      <div class="r" title="Timespan for captures of this URL">30 Sep 2016</div>
	      </div>
	  </td>
	  <td class="k">
	    <a href="" id="wm-graph-anchor">
	      <div id="wm-ipp-sparkline" title="Explore captures for this URL" style="position: relative">
		<canvas id="wm-sparkline-canvas" width="575" height="27" border="0"></canvas>
	      </div>
	    </a>
	  </td>
	</tr>
      </tbody>
    </table>
    <div style="position:absolute;bottom:0;right:2px;text-align:right;">
      <a id="wm-expand" class="wm-btn wm-closed" href="#expand" onclick="__wm.ex(event);return false;"><span id="wm-expand-icon" class="iconochive-down-solid"></span> <span style="font-size:80%">About this capture</span></a>
    </div>
  </div>
    <div id="wm-capinfo" style="border-top:1px solid #777;display:none; overflow: hidden">
            <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center">COLLECTED BY</div>
    <div style="padding:3px;position:relative" id="wm-collected-by-content">
            <div style="display:inline-block;vertical-align:top;width:50%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/ArchiveIt-Partner-593);"></span>
		Organization: <a style="color:#33f;" href="https://archive.org/details/ArchiveIt-Partner-593" target="_new"><span class="wm-title">Government Printing Office</span></a>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  Archive-It Partner 593: Government Printing Office
	</div>
	      </div>
      <div style="display:inline-block;vertical-align:top;width:49%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/ArchiveIt-Collection-5265)"></span>
		<div>Collection: <a style="color:#33f;" href="https://archive.org/details/ArchiveIt-Collection-5265" target="_new"><span class="wm-title">National Guideline Clearinghouse</span></a></div>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  NGC is an initiative of the Agency for Healthcare Research and Quality (AHRQ) External Web Site Policy, U.S. Department of Health and Human Services. NGC was originally created by AHRQ in partnership with the American Medical Association and the American Association of Health Plans (now America's Health Insurance Plans [AHIP]).

The NGC mission is to provide physicians and other health professionals, health care providers, health plans, integrated delivery systems, purchasers, and others an accessible mechanism for obtaining objective, detailed information on clinical practice guidelines and to further their dissemination, implementation, and use.
	</div>
	      </div>
    </div>
    <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center" title="Timestamps for the elements of this page">TIMESTAMPS</div>
    <div>
      <div id="wm-capresources" style="margin:0 5px 5px 5px;max-height:250px;overflow-y:scroll !important"></div>
      <div id="wm-capresources-loading" style="text-align:left;margin:0 20px 5px 5px;display:none"><img src="/static/images/loading.gif" alt="loading" /></div>
    </div>
  </div></div></div></div><script type="text/javascript">
__wm.bt(575,27,25,2,"web","https://www.guideline.gov/summaries/downloadcontent/ngc-10342?contentType=xml","2016-09-30",1996);
</script>
<!-- END WAYBACK TOOLBAR INSERT --><version>
  <xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource>
  <section secid="390" ordby="100" name="General">
    <field fieldid="161" ordby="105" id="391" name="Guideline Title" type="text">
      <fieldvalue value="<div class=&quot;content_title&quot;>Special considerations in pregnancy. In: British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011.</div>"/>
    </field>
    <field fieldid="97" ordby="110" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>Greig JM, Wood CGA, Clarke SU. Special considerations in pregnancy. In: British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. HIV Med. 2011 Sep;12(Suppl 2):102-8. [67 references]</td></tr></table>"/>
    </field>
    <field fieldid="120" ordby="115" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p></div>"/>
    </field>
  </section>
  <section secid="420" ordby="300" name="Recommendations">
    <field fieldid="151" ordby="310" id="421" name="Major Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Level of evidence (<strong>I&amp;ndash;IV</strong>) ratings are defined at the end of the &quot;Major Recommendations&quot; field.</p>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Background and Epidemiology</span></strong></p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Opportunistic infections in human immunodeficiency virus (HIV)-seropositive pregnant women should be managed with close collaboration between HIV specialists, obstetricians, paediatricians and where possible, specialists in obstetric medicine and materno&amp;ndash;foetal medicine (<strong>IV</strong>). </li>
    <li>Therapeutic drug monitoring (TDM) should always be considered due to altered drug pharmacokinetics in pregnancy, and the potential for complicated multiple interactions between antiretrovirals and many of the drugs used to treat opportunistic infections (Kaplan et al., 2009; Back, Gibbons, &amp;amp; Khoo, 2006). </li>
</ul>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Diagnostic Considerations in HIV-seropositive Pregnant Women</span></strong></p>
<p><strong>Radiology</strong></p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>When choosing imaging modality for the diagnosis of opportunistic infections in pregnant women consideration should be given to the need for a rapid diagnosis and the potential harm of the investigation. Discussion between HIV specialists, obstetricians and senior radiologist is recommended (<strong>IV</strong>). </li>
</ul>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Diagnostic Considerations for the Foetus and Newborn Baby</span></strong></p>
<p><strong>Vertical Transmission of Maternal Opportunistic Infections to the Neonate</strong></p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Neonates born to HIV-seropositive women should be assessed by a paediatrician, and where necessary actively screened, for congenital opportunistic infections. The placenta should also be examined histologically for signs of infection or disease (<strong>IV</strong>). </li>
</ul>
<p>Refer to the original guideline document for treatment considerations for other specific opportunistic infections during pregnancy.</p>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Definitions</span></strong>:</p>
<p><strong>Level of Evidence</strong></p>
<table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Level of Evidence&quot;>
    <tbody>
        <tr>
            <th width=&quot;5%&quot; class=&quot;Center&quot; valign=&quot;top&quot;>Ia</th>
            <td valign=&quot;top&quot;>Evidence obtained from meta-analysis of randomized controlled trials</td>
        </tr>
        <tr>
            <th class=&quot;Center&quot; valign=&quot;top&quot;>Ib</th>
            <td valign=&quot;top&quot;>Evidence obtained from at least one randomized controlled trial</td>
        </tr>
        <tr>
            <th class=&quot;Center&quot; valign=&quot;top&quot;>IIa</th>
            <td valign=&quot;top&quot;>Evidence obtained from at least one well designed controlled study without randomization</td>
        </tr>
        <tr>
            <th class=&quot;Center&quot; valign=&quot;top&quot;>IIb</th>
            <td valign=&quot;top&quot;>Evidence obtained from at least one other type of well designed quasi-experimental study</td>
        </tr>
        <tr>
            <th class=&quot;Center&quot; valign=&quot;top&quot;>III</th>
            <td valign=&quot;top&quot;>Evidence obtained from well designed non-experimental descriptive studies</td>
        </tr>
        <tr>
            <th class=&quot;Center&quot; valign=&quot;top&quot;>IV</th>
            <td valign=&quot;top&quot;>Evidence obtained from expert committee reports or opinions and/or clinical experience of respected authorities</td>
        </tr>
    </tbody>
</table></div>"/>
    </field>
    <field fieldid="138" ordby="330" id="423" name="Clinical Algorithm(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None provided</p></div>"/>
    </field>
  </section>
  <section secid="396" ordby="400" name="Scope">
    <field fieldid="140" ordby="405" id="397" name="Disease/Condition(s)" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Opportunistic infections </li>
    <li>Pregnancy </li>
    <li>Human immunodeficiency virus (HIV) seropositivity </li>
</ul>"/>
    </field>
    <field fieldid="103" ordby="410" id="398" name="Guideline Category" type="picklist-many">
      <fieldvalue value="Diagnosis"/>
      <fieldvalue value="Evaluation"/>
      <fieldvalue value="Management"/>
      <fieldvalue value="Prevention"/>
      <fieldvalue value="Screening"/>
      <fieldvalue value="Treatment"/>
    </field>
    <field fieldid="113" ordby="415" id="399" name="Clinical Specialty" type="picklist-many">
      <fieldvalue value="Family Practice"/>
      <fieldvalue value="Infectious Diseases"/>
      <fieldvalue value="Internal Medicine"/>
      <fieldvalue value="Obstetrics and Gynecology"/>
      <fieldvalue value="Pediatrics"/>
      <fieldvalue value="Pharmacology"/>
      <fieldvalue value="Preventive Medicine"/>
      <fieldvalue value="Radiology"/>
    </field>
    <field fieldid="114" ordby="420" id="400" name="Intended Users" type="picklist-many">
      <fieldvalue value="Advanced Practice Nurses"/>
      <fieldvalue value="Pharmacists"/>
      <fieldvalue value="Physician Assistants"/>
      <fieldvalue value="Physicians"/>
    </field>
    <field fieldid="129" ordby="425" id="401" name="Guideline Objective(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>To help physicians in the United Kingdom investigate and manage human immunodeficiency virus (HIV)-seropositive pregnant patients suspected of or having an opportunistic infection</p></div>"/>
    </field>
    <field fieldid="132" ordby="430" id="402" name="Target Population" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Human immunodeficiency virus (HIV)-seropositive, pregnant patients suspected of or having an opportunistic infection and their foetuses and newborn infants</p></div>"/>
    </field>
    <field fieldid="133" ordby="435" id="403" name="Interventions and Practices Considered" type="text">
      <fieldvalue value="<ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;>
    <li>Close collaboration between human immunodeficiency virus (HIV) specialists, obstetricians, paediatricians, and specialists in obstetric medicine and materno&amp;ndash;foetal medicine </li>
    <li>Therapeutic drug monitoring (TDM) </li>
    <li>Safety considerations for choice of imaging modalities during pregnancy (x-rays, computed tomography [CT], magnetic resonance imaging [MRI], and use of contrast) </li>
    <li>Screening newborns for congenital opportunistic infections </li>
    <li>Treatment considerations for specific opportunistic infections </li>
</ol>"/>
    </field>
    <field fieldid="134" ordby="440" id="404" name="Major Outcomes Considered" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Morbidity and mortality (maternal and fetal) </li>
    <li>Adverse events related to therapy and drug interactions </li>
    <li>Vertical transmission of maternal opportunistic infection to the neonate (congenital infection) </li>
    <li>Teratogenic effects of drugs </li>
    <li>Risk of birth defects </li>
    <li>Effectiveness of drug treatments </li>
</ul>"/>
    </field>
  </section>
  <section secid="405" ordby="500" name="Methodology">
    <field fieldid="109" ordby="505" id="406" name="Methods Used to Collect/Select the Evidence" type="picklist-many">
      <fieldvalue value="Searches of Electronic Databases"/>
    </field>
    <field fieldid="135" ordby="510" id="407" name="Description of Methods Used to Collect/Select the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>All information considered had to have been published in a peer review journal or presented at an international human immunodeficiency virus (HIV) meeting in abstract form. Inclusion/exclusion criteria essentially required that the information was relevant to the diagnosis, treatment or prevention of the specified opportunistic infection in HIV-positive individuals. Information of relevance to other related immunocompromised groups was also taken into consideration if the section authors felt relevant. Case reports were included and the review was not restricted only to clinical trials or meta-analyses. Search dates were from 1980 to January 2011.</p></div>"/>
    </field>
    <field fieldid="136" ordby="515" id="408" name="Number of Source Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not stated</p></div>"/>
    </field>
    <field fieldid="115" ordby="520" id="409" name="Methods Used to Assess the Quality and Strength of the Evidence" type="picklist-choice">
      <fieldvalue value="Weighting According to a Rating Scheme (Scheme Given)"/>
    </field>
    <field fieldid="149" ordby="525" id="410" name="Rating Scheme for the Strength of the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Level of Evidence</strong></p>
<table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Level of Evidence&quot;>
    <tbody>
        <tr>
            <th width=&quot;5%&quot; class=&quot;Center&quot; valign=&quot;top&quot;>Ia</th>
            <td valign=&quot;top&quot;>Evidence obtained from meta-analysis of randomized controlled trials</td>
        </tr>
        <tr>
            <th class=&quot;Center&quot; valign=&quot;top&quot;>Ib</th>
            <td valign=&quot;top&quot;>Evidence obtained from at least one randomized controlled trial</td>
        </tr>
        <tr>
            <th class=&quot;Center&quot; valign=&quot;top&quot;>IIa</th>
            <td valign=&quot;top&quot;>Evidence obtained from at least one well designed controlled study without randomization</td>
        </tr>
        <tr>
            <th class=&quot;Center&quot; valign=&quot;top&quot;>IIb</th>
            <td valign=&quot;top&quot;>Evidence obtained from at least one other type of well designed quasi-experimental study</td>
        </tr>
        <tr>
            <th class=&quot;Center&quot; valign=&quot;top&quot;>III</th>
            <td valign=&quot;top&quot;>Evidence obtained from well designed non-experimental descriptive studies</td>
        </tr>
        <tr>
            <th class=&quot;Center&quot; valign=&quot;top&quot;>IV</th>
            <td valign=&quot;top&quot;>Evidence obtained from expert committee reports or opinions and/or clinical experience of respected authorities</td>
        </tr>
    </tbody>
</table></div>"/>
    </field>
    <field fieldid="116" ordby="530" id="411" name="Methods Used to Analyze the Evidence" type="picklist-many">
      <fieldvalue value="Systematic Review"/>
    </field>
    <field fieldid="150" ordby="535" id="412" name="Description of the Methods Used to Analyze the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not stated</p></div>"/>
    </field>
    <field fieldid="112" ordby="540" id="413" name="Methods Used to Formulate the Recommendations" type="picklist-choice">
      <fieldvalue value="Expert Consensus"/>
    </field>
    <field fieldid="145" ordby="545" id="414" name="Description of Methods Used to Formulate the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not stated</p></div>"/>
    </field>
    <field fieldid="146" ordby="550" id="415" name="Rating Scheme for the Strength of the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable</p></div>"/>
    </field>
    <field fieldid="148" ordby="565" id="417" name="Cost Analysis" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>A formal cost analysis was not performed and published cost analyses were not reviewed.</p></div>"/>
    </field>
    <field fieldid="104" ordby="570" id="418" name="Method of Guideline Validation" type="picklist-choice">
      <fieldvalue value="Not stated"/>
    </field>
    <field fieldid="130" ordby="575" id="419" name="Description of Method of Guideline Validation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable</p></div>"/>
    </field>
  </section>
  <section secid="424" ordby="600" name="Evidence Supporting the Recommendations">
    <field fieldid="98" ordby="605" id="425" name="References Supporting the Recommendations" type="citation">
      <fieldvalue value="<table><tr><td>Back D, Gibbons S, Khoo S. An update on therapeutic drug monitoring for antiretroviral drugs. Ther Drug Monit. 2006 Jun;28(3):468-73. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16778736&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H, Centers for Disease Control and Prevention (CDC), National Institutes of Health, HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009 Apr 10;58(RR-4):1-207; quiz CE1-4. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19357635&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
    </field>
    <field fieldid="139" ordby="610" id="426" name="Type of Evidence Supporting the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The type of supporting evidence is identified and graded for most recommendations (see the &quot;Major Recommendations&quot; field).</p></div>"/>
    </field>
  </section>
  <section secid="427" ordby="700" name="Benefits/Harms of Implementing the Guideline Recommendations">
    <field fieldid="152" ordby="705" id="428" name="Potential Benefits" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Accurate diagnosis and appropriate treatment of opportunistic infections in pregnant, human immunodeficiency virus (HIV)-seropositive individuals</p></div>"/>
    </field>
    <field fieldid="153" ordby="710" id="429" name="Potential Harms" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Where an opportunistic infection is being treated, the foetus should be closely monitored, for example by serial high-resolution ultrasound scans and foetal cardiac monitoring, so that signs of disease, growth retardation, foetal distress or possible drug toxicity in the foetus can be detected early. </li>
    <li>Refer to section 11.4 in the original guideline document, &quot;Treatment considerations for specific opportunistic infections,&quot; for a discussion of safety concerns for drugs used during pregnancy. Also refer to Appendix 1 in the original guideline document for side effects of certain drug formulations. </li>
</ul>"/>
    </field>
  </section>
  <section secid="430" ordby="800" name="Contraindications">
    <field fieldid="144" ordby="805" id="431" name="Contraindications" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Plain abdominal X-rays should generally be avoided during pregnancy. </li>
    <li>A direct computed tomography (CT) scan of the foetus in the pregnant abdomen is contraindicated and, where possible, should be avoided. Magnetic resonance imaging (MRI) scanning of the foetus and abdomen may be considered, although it is recommended to avoid them in the first trimester unless absolutely necessary. </li>
    <li>Gadolinium, which is used in MRI scanning, is not recommended as it has been found to be teratogenic in some animal studies, and should be avoided if possible. </li>
    <li>Refer to section 11.4 in the original guideline document, &quot;Treatment considerations for specific opportunistic infections,&quot; for a discussion of safety concerns for drugs used during pregnancy, many of which should be avoided in the first trimester of pregnancy. </li>
    <li>Refer to Appendix 1 in the original guideline document for contraindications of certain drug formulations. </li>
</ul>"/>
    </field>
  </section>
  <section secid="432" ordby="900" name="Qualifying Statements">
    <field fieldid="137" ordby="905" id="433" name="Qualifying Statements" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>These guidelines are primarily intended to guide practice in the United Kingdom and related health systems. Although it is hoped they can provide some guidance in developed countries there are some important distinctions in this environment and individual recommendations may not be as applicable in this setting. </li>
    <li>In the appendices in the original guideline document there is an A&amp;ndash;Z of drugs used in the management of opportunistic infections. This is intended as a guideline but readers are advised to follow the discussion of dosing and the evidence for specific treatments provided in the text. In some cases alternative treatments are provided in the appendix in the original guideline document. These are not discussed in the text and these are mainly of historical interest and readers should be aware that these are not, in general, supported by the evidence base for treatments discussed in the text. It should also be noted that as evidence of drug toxicity, interactions, pregnancy risk and cost is rapidly evolving the table should be considered in association with the updated summary of product characteristics (SPC) for the agent and other relevant sources of drug information. </li>
    <li>Recommendations based upon expert opinion have the least evidence but perhaps provide an important reason for writing the guidelines: to produce a consensual opinion about current practice. It must, however, be appreciated that such opinion is not always correct and alternative practices may be equally valid. The recommendations contained in these guidelines should therefore be viewed as guidelines in the true spirit of the term. They are not designed to be restrictive nor should they challenge research into current practice. Similarly, although the British HIV Association (BHIVA) Opportunistic Infection Guidelines Group seeks to provide guidelines to optimize treatment, such care needs to be individualized and the authors have not constructed a document that they would wish to see used as a 'standard' for litigation. </li>
    <li>The clinical care of patients with known or suspected opportunistic infections (OIs) requires a multidisciplinary approach, drawing on the skills and experience of all healthcare professional groups. Moreover, these guidelines emphasize that inpatients with human immunodeficiency virus (HIV)-related disease often need rapid access to a variety of diagnostic tests and radiological interventions that may not be immediately available at local hospitals. Furthermore, expert interpretation of these tests by supporting specialties such as radiology, histopathology, microbiology and virology is often required. Optimal care of opportunistic infection can only be achieved by the close cooperation of these healthcare professionals and unless all are intimately involved in the care of patients, it is likely that the outcome will be less favourable. In keeping with BHIVA standards for HIV clinical care, patients needing inpatient care for HIV-related disease should ordinarily be admitted to an HIV centre or the relevant tertiary service in liaison with the HIV centre. </li>
</ul>"/>
    </field>
  </section>
  <section secid="434" ordby="1000" name="Implementation of the Guideline">
    <field fieldid="131" ordby="1010" id="436" name="Description of Implementation Strategy" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>An implementation strategy was not provided.</p></div>"/>
    </field>
    <field fieldid="117" ordby="1015" id="437" name="Implementation Tools" type="picklist-many">
      <fieldvalue value="Mobile Device Resources"/>
    </field>
  </section>
  <section secid="439" ordby="1100" name="Institute of Medicine (IOM) National Healthcare Quality Report Categories">
    <field fieldid="50" ordby="1105" id="440" name="IOM Care Need" type="picklist-many">
      <fieldvalue value="Getting Better"/>
      <fieldvalue value="Living with Illness"/>
      <fieldvalue value="Staying Healthy"/>
    </field>
    <field fieldid="51" ordby="1110" id="441" name="IOM Domain" type="picklist-many">
      <fieldvalue value="Effectiveness"/>
      <fieldvalue value="Patient-centeredness"/>
      <fieldvalue value="Safety"/>
    </field>
  </section>
  <section secid="442" ordby="1200" name="Identifying Information and Availability">
    <field fieldid="97" ordby="1201" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>Greig JM, Wood CGA, Clarke SU. Special considerations in pregnancy. In: British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. HIV Med. 2011 Sep;12(Suppl 2):102-8. [67 references]</td></tr></table>"/>
    </field>
    <field fieldid="124" ordby="1205" id="443" name="Adaptation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable: The guideline was not adapted from another source.</p></div>"/>
    </field>
    <field fieldid="128" ordby="1215" id="445" name="Date Released" type="text">
      <fieldvalue value="2011 Sep"/>
    </field>
    <field fieldid="158" ordby="1225" id="447" name="Guideline Developer(s)" type="orglist-p">
      <fieldvalue value="British HIV Association - Disease Specific Society"/>
      <fieldvalue value="British Infection Association - Professional Association"/>
    </field>
    <field fieldid="125" ordby="1235" id="449" name="Source(s) of Funding" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>British HIV Association</p></div>"/>
    </field>
    <field fieldid="126" ordby="1240" id="450" name="Guideline Committee" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>BHIVA Guidelines Writing Group on Opportunistic Infection</p></div>"/>
    </field>
    <field fieldid="127" ordby="1245" id="451" name="Composition of Group That Authored the Guideline" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><em>Section Authors</em>: JM Greig, Royal Hallamshire Hospital, Sheffield, UK; CGA Wood, North Middlesex University Hospital, London, UK; SU Clarke, St James's Hospital, Dublin, Ireland</p>
<p><em>Group Joint Chair</em>: Dr Mark Nelson, Chelsea &amp;amp; Westminster Hospital, London, UK</p>
<p><em>Group Joint Chair</em>: Professor David Dockrell, University of Sheffield, UK</p>
<p><em>Group Joint Chair</em>: Dr Simon Edwards, Mortimer Market Centre, London, UK</p>
<p><em>Writing Group Members</em>: Dr Brian Angus, John Radcliffe Hospital, Oxford, UK; Dr Simon Barton, Chelsea &amp;amp; Westminster Hospital, London, UK; Dr Nick Beeching, Liverpool School of Tropical Medicine, UK; Prof Colm Bergin, St James's Hospital, Dublin, Ireland; Dr Marta Boffito, Chelsea &amp;amp; Westminster Hospital, London, UK; Dr Ronan Breen, Royal Free Hospital, London, UK; Dr Jonathan Cartledge, Mortimer Market Centre, London, UK; Dr Susan Clarke, St James's Hospital, Dublin, Ireland; Dr Martin Fisher, Brighton and Sussex University Hospital, Brighton, UK; Dr Andrew Freedman, Cardiff University School of Medicine, UK; Prof Brian Gazzard, Chelsea &amp;amp; Westminster Hospital, London, UK; Dr Alison Grant, London School of Hygiene and Tropical Medicine, UK; Dr Julia Greig, Royal Hallamshire Hospital, Sheffield, UK; Dr Rachael Jones, Chelsea &amp;amp; Westminster Hospital, London, UK; Prof Saye Khoo, University of Liverpool; Prof Clifford Leen, Edinburgh University, UK; Dr Marc Lipman, Royal Free Hospital, London, UK; Dr Hadi Manji, National Hospital for Neurology &amp;amp; Neurosurgery, London, UK; Prof Robert Miller, Mortimer Market Centre, London, UK; Miss Suzanne Mitchell, Chelsea and Westminster Hospital, London, UK; Dr Ed Ong, Newcastle General Hospital, UK; Dr Anton Pozniak, Chelsea &amp;amp; Westminster Hospital, London, UK; Dr Matthias Schmid, Newcastle General Hospital, UK; Miss Marianne Shiew, Chelsea &amp;amp; Westminster Hospital, London, UK; Prof Mervyn Singer, University College London, UK; Dr Ed Wilkins, North Manchester General Hospital, UK; Dr Ian Williams, Royal Free and University College Medical School, London, UK; Dr Chris Wood, North Middlesex University Hospital, London, UK; Ms Rosy Weston, St Mary's Hospital, Imperial College, London, UK</p></div>"/>
    </field>
    <field fieldid="147" ordby="1250" id="452" name="Financial Disclosures/Conflicts of Interest" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The British HIV Association (BHIVA) has a clear policy of declarations of interests within the Association:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>BHIVA requires that all members of guidelines writing groups, as well as any expert external peer reviewers, must declare all interests and membership of other committees retrospectively on an annual basis, to give protection to individuals working as members of writing groups. </li>
    <li>All members of guidelines writing groups must undertake a declaration of interests prior to serving on a writing group and this declaration is confirmed and repeated at the publication of each set of completed guidelines published. </li>
    <li>The details given in declaration forms are retained on a register at the Secretariat and can be made available for publication, if required. </li>
</ul></div>"/>
    </field>
    <field fieldid="120" ordby="1256" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p></div>"/>
    </field>
    <field fieldid="118" ordby="1260" id="454" name="Guideline Availability" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Electronic copies: Available from the <a href=&quot;http://www.bhiva.org/documents/Guidelines/OI/hiv_v12_is2_Iss2Press_Text.pdf&quot; title=&quot;British HIV Association (BHIVA) Web site&quot;>British HIV Association (BHIVA) Web site</a>. Also available as a smartphone app from the <a href=&quot;http://www.bhiva.org/Apps.aspx&quot; title=&quot;British HIV Association (BHIVA) Web site&quot;>BHIVA Web site</a>.</p></div>"/>
    </field>
    <field fieldid="119" ordby="1265" id="455" name="Availability of Companion Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None available</p></div>"/>
    </field>
    <field fieldid="143" ordby="1275" id="457" name="Patient Resources" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None available</p></div>"/>
    </field>
    <field fieldid="142" ordby="1280" id="458" name="NGC Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary was completed by ECRI Institute on July 30, 2014.</p></div>"/>
    </field>
    <field fieldid="141" ordby="1290" id="460" name="Copyright Statement" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.</p></div>"/>
    </field>
  </section>
  <section secid="99999" ordby="99999" name="Disclaimer">
    <field fieldid="99999" ordby="99999" id="99999" name="NGC Disclaimer" type="text">
      <fieldvalue value="<p>The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <a href=&quot;/about/inclusion-criteria.aspx&quot;>http://www.guideline.gov/about/inclusion-criteria.aspx</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p>"/>
    </field>
  </section>
</version><!--
     FILE ARCHIVED ON 19:19:01 Sep 30, 2016 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 00:14:30 Jul 16, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 57.838 (3)
  esindex: 0.011
  captures_list: 76.457
  CDXLines.iter: 13.411 (3)
  PetaboxLoader3.datanode: 63.872 (4)
  exclusion.robots: 0.472
  exclusion.robots.policy: 0.449
  RedisCDXSource: 0.823
  PetaboxLoader3.resolve: 154.329
  load_resource: 183.901
-->